Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

Summary

Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.

Timeline

Start

2020-09-21

Primary completion

2020-11-18

Completion

2020-11-18

Outcome

Outcome not reported

Stopped: “Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19 did not meet their primary efficacy endpoints. Based on this higher management made the decision to prematurely terminate the D822FC00005 PK study.”

Drugs

Indications